Precision Business Insights
Portfolio

 

Oxytocic Pharmaceuticals Market

: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Oxytocic Pharmaceuticals Market: By Product Type (Intramuscular Injection, Intravenous Injection), By Source (Natural Oxytocin (Animal Pituitary Extracts), Synthetic Oxytocin), By End-User (Maternity Clinics, Hospitals), and Geography 

 

 

Market Dynamics: Oxytocic Pharmaceuticals Market

 

Oxytocin is a female reproductive hormone secreted in the hypothalamus and released into blood circulation during childbirth to induce the labor and milk production in mothers. It is also used as uterotonic (induce uterine contractions) and reduce the hemorrhage after C-section. Increase in the number of preterm births, rise in labor induction rates, escalation in complicated pregnancy cases in developing countries, and increase in awareness about maternal health are anticipated to propel the oxytocic pharmaceuticals market. However, adverse effects associated with oxytocic drugs may restrain the growth of oxytocic drugs market over the forecast period.

 

Market Scope:

Globally This market segmented on the basis of product type, source, end user, and region

Based on product type, the market is segmented into the following

  • Intramuscular Injection
  • Intravenous Injection

Based on the source, the market is segmented into the following

  • Natural Oxytocin (Animal Pituitary Extracts)
  • Synthetic Oxytocin

Based on the end user, the market is segmented into the following

  • Maternity Clinics
  • Hospitals

Based on the region, the market is segmented into the following

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Regional Analysis:

Geographically, global oxytocic pharmaceuticals market segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America oxytocic pharmaceuticals market is growing due to rise in incidence of induced labor, high awareness about oxytocic drugs, and rise in awareness about maternal health. Europe oxytocic pharmaceuticals market has a lucrative growth, which is attributed to presence of huge number of companies manufacturing the oxytocin drugs and rise in oxytocin usage during labor in the region. Asia Pacific oxytocic pharmaceuticals market is poised to grow at significant rate due to rise in childbirths in India and China, increase in female population, and rise in awareness about oxytocic drugs among healthcare professionals. Latin America oxytocic pharmaceuticals market has a notable share owing to increase in adolescent pregnancies in Brazil and rise in labor induction procedures. Middle East and Africa oxytocic pharmaceuticals market growth driven by higher prevalence of post-partum hemorrhage due to lack of nutrition in pregnant women and rise in awareness about pregnancy-related issues among healthcare professionals.

 

Competition Assessment:

Key players’ profiles in the global oxytocic pharmaceuticals market include

  • Pfizer, Inc. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Novartis AG (Switzerland)
  • Cardinal Health (U.S.)
  • Ferring Pharmaceuticals B.V. (Switzerland)
  • Par Pharmaceutical, Inc. (U.S.)

 

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Pfizer, Inc. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Novartis AG (Switzerland)
  • Cardinal Health (U.S.)
  • Par Pharmaceutical, Inc. (U.S.)